Joseph Boccuzi - Allergan Plc Independent Director

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>AP</div>
AGN -- USA Stock  

Earnings Report: 4th of August 2020  

  Director
Mr. Joseph H. Boccuzi serves as Independent Director of the Company. Mr. Boccuzi retired from Spencer Stuart in December 2016 after 24 years of service, where he played a central role in establishing and building the firms Life Sciences Practice. He served in positions of increasing responsibility within Spencer Stuart, most recently as a Partner in the firms Global Life Sciences, Board and Chief Executive Officer Practices, a role he had held since 1996. Prior to joining Spencer Stuart, Mr. Boccuzi worked in executive search, VC and corporate management roles. He served as a consultant with Paul R. Ray Company, an executive search firm. Prior to that, he worked as a Financial Advisor for Merrill Lynch. Mr. Boccuzi also held several leadership positions at National Patent Development Corporationrationration, a VC firm specializing in medical technology and investment throughout the U.S. and worldwide. While there, he managed four medical startup operations serving as chief operating officer, board member and adviser to the board of directors. Prior to that, Mr. Boccuzi worked in sales for Xerox Corporationrationration.
Age: 71  Director Since 2017      
862 261 7000  http://www.allergan.com

Allergan Plc Management Efficiency

Allergan Plc has Return on Asset of (0.0564) % which means that on every $100 spent on asset it lost $0.0564. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (0.0913) % meaning that it generated no profit with money invested by stockholders. Allergan Plc management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities.
The company has 23.08 B in debt with debt to equity (D/E) ratio of 39.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. Allergan Plc has Current Ratio of 0.98 suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Scott GottliebPfizer Inc
2019
Sanjay KhoslaZoetis Inc
2013
Joseph EchevarriaPfizer Inc
2015
Dan LittmanPfizer Inc
2018
Jeffrey SmithPerrigo Company Plc
2017
Ravi BhoothalingamDr Reddys Laboratories
2000
William DoyleZoetis Inc
2015
Jeffrey KindlerPerrigo Company Plc
2017
Geoffrey ParkerPerrigo Company Plc
2016
Ronald BlaylockPfizer Inc
2017
Rolf ClassonPerrigo Company Plc
2017
Susan HockfieldPfizer Inc
2020
Ellen HoffingPerrigo Company Plc
2008
Anthony ColesRegeneron Pharmaceuticals
2017
Ashok GangulyDr Reddys Laboratories
2009
Dennis AusielloPfizer Inc
2015
Gary KunklePerrigo Company Plc
2009
Gary CohenPerrigo Company Plc
2009
Omkar GoswamiDr Reddys Laboratories
2000
Huda ZoghbiRegeneron Pharmaceuticals
2016
Gregory NordenZoetis Inc
2013

Company Summary

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc. Allergan Plc operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 17400 people.Allergan Plc (AGN) is traded on New York Stock Exchange in USA and employs 17,400 people.

Allergan Plc Leadership Team

Matthew Walsh, Chief Financial Officer, Executive Vice President
Robert Bailey, Chief Legal Officer and Corporate Secretary
Robert Stewart, Executive VP and President of Generic and Global Operations
Ronald Taylor, Independent Director
Adriane Brown, Independent Director
William Meury, Executive Vice President, Chief Commercial Officer
Brenton Saunders, Chairman of the Board, President, Chief Executive Officer
Wayne Swanton, Executive Vice President - Global Operations
Robert Hugin, Independent Director
Nicholson, Chief R&D Officer
Christopher Bodine, Independent Director
Karen Ling, Chief Human Resource Officer, Executive Vice President
Michael Gallagher, Lead Independent Director
Paul Bisaro, Executive Chairman
Thomas Freyman, Independent Director
Catherine Klema, Lead Independent Director
James DArecca, Chief Accounting Officer
Christopher Coughlin, Lead Independent Director
Nesli Basgoz, Independent Director
Philippe Schaison, Executive Vice President and President Allergan Medical
Maria Hilado, CFO and Executive VP
Joseph Boccuzi, Independent Director
Patrick OSullivan, Independent Director
Fred Weiss, Independent Director
A Bailey, Executive Vice President, Chief Legal Officer and Corporate Secretary
Alex Kelly, Chief Communications Officer
CDavid Nicholson, Executive Vice President, Chief R&D Officer
Carol Davidson, Independent Director
Michael Greenberg, Independent Director
Ron Taylor, Independent Director
Jonathon Kellerman, Executive Vice President Chief Compliance Officer
Paul Navarre, Executive Vice President and President International Brands
James Bloem, Independent Director
Karina Calzadilla, IR Contact Officer
Peter McDonnell, Independent Director

Stock Performance Indicators

Current Sentiment - AGN

Allergan Plc Investor Sentiment

Predominant part of Macroaxis users are presently bullish on Allergan Plc. What is your sentiment towards investing in Allergan Plc? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Allergan Plc Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Allergan Plc and Vertex Pharmaceuticals. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page